methyl (S)-2-((tert-butoxycarbonyl)amino)-2-cyclohexylacetate | 169512-95-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: methyl (S)-2-((tert-butoxycarbonyl)amino)-2-cyclohexylacetate
• 英文别名: N-BOC-a-cyclohexylglycine, methyl ester；methyl 2-cyclohexyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]acetate
• CAS: 169512-95-2
• 化学式: C₁₄H₂₅NO₄
• 分子量: 271.357
• InChiKey: ABLGTTUCCPCVGX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  二碳酸二叔丁酯 在 Rh/Al₂O₃ 、 氢气 、 溶剂黄146 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 25.0~35.0 ℃ 、500.01 kPa 条件下， 生成 methyl (S)-2-((tert-butoxycarbonyl)amino)-2-cyclohexylacetate 、 methyl 2-(tert-butoxycarbonylamino)-2-(4-hydroxycyclohexyl)acetate
  参考文献：
  名称：

  A Multikilogram-Scale Synthesis of (R)-Methyl 2-[(1r,4R)-4-(tert-Butoxy­carbonylamino)cyclohexyl]-2-(2-nitrophenylsulfonamido)acetate - A Doubly Protected Building Block with Three Points of Variation

  摘要：

  报告了 2-[(1r,4R)-4-(叔丁氧羰基氨基)环己基]-2-(2-硝基苯磺酰胺基)乙酸(R)-甲基酯的可靠且可扩展的合成方法。它是制备反式取代氨基环己烷的支架。关键的合成步骤是还原 d-4- 羟基苯甘氨酸或受保护的等价物，以实现环己基环上所需的区域化学反应。

  DOI：

  10.1055/s-0031-1289724

文献信息

• [EN] PYRROLO [2, 3 - B] PYRAZINE - 7 - CARBOXAMIDE DERIVATIVES AND THEIR USE AS JAK AND SYK INHIBITORS<br/>[FR] DÉRIVÉS DE PYRROLO[2,3-B]PYRAZINE-7-CARBOXAMIDE ET LEUR UTILISATION COMME INHIBITEURS DE JAK ET SYK
  申请人：HOFFMANN LA ROCHE

  公开号：WO2011144585A1

  公开（公告）日：2011-11-24

  The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula (I), wherein the variables Q and R, R2, and R3 are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.

  本发明涉及使用式（I）的新型吡咯吡嗪衍生物，其中变量Q和R，R2和R3如本文所述定义，其抑制JAK和SYK并且适用于治疗自身免疫和炎症性疾病。
• HCV NS-3 serine protease inhibitors
  申请人：Tibotec Pharmaceuticals Ltd.

  公开号：EP1881001A1

  公开（公告）日：2008-01-23

  HCV inhibitors, compositions comprising these compounds as active ingredient, as well as processes for preparing these compounds, having the formula I wherein A is

  HCV抑制剂，包含这些化合物作为活性成分的组合物，以及制备这些化合物的过程，其化学式为I，其中A是。
• Chiral Bis(imidazolidine)-Derived NCN Pincer Rh Complex for Catalytic Asymmetric Mannich Reaction of Malononitrile with<i>N</i>-Boc Imines
  作者：Takayoshi Arai、Takuma Moribatake、Hyuma Masu

  DOI：10.1002/chem.201502097

  日期：2015.7.20

  Chiral bis(imidazolidine)‐derived NCN–rhodium complexes ([PhBidine‐RhX2] and [tBu‐PhBidine‐RhX2]) were prepared by a CH insertion method, and the structures were unequivocally determined by X‐ray crystallographic analysis. The [tBu‐PhBidine‐Rh(OAc)2] complex smoothly catalyzed an asymmetric Mannich reaction of malononitrile with N‐Boc imines to give products in up to 94 % ee, which are useful for

  手性双（咪唑）衍生NCN -铑配合物（[PhBidine-RHX 2 ]和[吨卜PhBidine-RHX 2 ]）通过一个C制备 ħ插入方法，和结构进行了明确地通过X射线晶体学确定的分析。[ t Bu-PhBidine-Rh（OAc）2 ]配合物平稳地催化了丙二腈与N -Boc亚胺的不对称曼尼希反应，从而产生了94％ee以上的产物，可用于合成手性α-氨基酸。
• Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides
  申请人：——

  公开号：US20020002268A1

  公开（公告）日：2002-01-03

  The present invention relates to azacycloalkylalkanoyl peptides and pseudopeptides which inhibit platelet aggregation and thrombus formation thereby being useful in the prevention and treatment of thrombosis associated with disease states such as myocardial infarction, stroke, peripheral arterial disease, and disseminated intravascular coagulation, to methods for the prevention or treatment of thrombosis in a mammal in need of such therapy comprising the administration of a therapeutically effective amount of such compounds, and to pharmaceutical compositions comprising such compounds.

  本发明涉及抑制血小板聚集和血栓形成的氮杂环烷基烷酰肽和伪肽，因此在预防和治疗与疾病状态相关的血栓形成，如心肌梗死、中风、外周动脉疾病和弥漫性血管内凝血等方面具有用处，以及用于预防或治疗哺乳动物中需要此类治疗的方法，包括给予这些化合物的治疗有效量，以及包含这些化合物的制药组合物。
• HCV NS-3 Serine Protease Inhibitors
  申请人：Rosenquist Asa

  公开号：US20100003216A1

  公开（公告）日：2010-01-07

  Compounds of the formula where the variables are as defined in the specification inhibit the NS3 protease of flavivirus sych as hepatitis C virus (HCV). The compounds comprise a novel linkage between a heterocyclic P2 unit and those portions of the inhibitor more distal to the nominal cleavage site of the native substrate, which linkage reverses the orientation of peptidic bonds on the distal side relative to those proximal to the cleavage site.

  式中的变量如规范中所定义，可以抑制黄热病病毒(NS3蛋白酶)等黄病毒的蛋白酶，如丙型肝炎病毒(HCV)。这些化合物包括一个新的链接，连接一个杂环P2单位和那些离原生底物的名义剪切位点更远的抑制剂部位，该链接将离剪切位点远侧的肽键的方向与靠近剪切位点的肽键的方向相反。